Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DAT-1604 Tablets as Monotherapy in the Advanced Solid Tumor

NCT06998173 is registered in ClinicalTrials.gov with Danatlas Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT06998173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DAT-1604 Tablets as Monotherapy in the Advanced Solid Tumor
Lead sponsor
Danatlas Pharmaceuticals Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 31, 2025
Completion date
July 30, 2028
Enrollment
228 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors